The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 30, 2016

Filed:

May. 31, 2013
Applicant:

Taisho Pharmaceutical Co., Ltd., Toshima-ku, Tokyo, JP;

Inventors:

Takashi Hashihayata, Toshima-ku, JP;

Norikazu Otake, Toshima-ku, JP;

Naoki Miyakoshi, Toshima-ku, JP;

Kazunari Sakagami, Toshima-ku, JP;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 207/08 (2006.01); C07D 307/88 (2006.01); C07C 323/60 (2006.01); A61K 31/357 (2006.01); C07C 237/04 (2006.01); C07C 271/24 (2006.01); C07C 237/20 (2006.01); A61K 31/265 (2006.01); C07D 317/50 (2006.01); C07D 317/40 (2006.01); C07C 229/50 (2006.01);
U.S. Cl.
CPC ...
C07D 317/50 (2013.01); A61K 31/265 (2013.01); A61K 31/357 (2013.01); C07C 229/50 (2013.01); C07C 237/04 (2013.01); C07C 237/20 (2013.01); C07C 271/24 (2013.01); C07C 323/60 (2013.01); C07D 207/08 (2013.01); C07D 307/88 (2013.01); C07D 317/40 (2013.01); C07C 2101/14 (2013.01); C07C 2101/18 (2013.01); C07C 2102/18 (2013.01); C07C 2103/74 (2013.01);
Abstract

Provided are a fluorine-containing amino acid prodrug represented by general formula (I) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmaceutically acceptable salt thereof. More specifically, provided is a prodrug that increases the in vivo exposure and enhances the oral absorbability and other mucosal absorbability of a parent compound that acts on group 2 metabotropic glutamate receptors as an agent for the treatment or prevention of diseases in which group 2 metabotropic glutamate receptors are said to be involved, such as: schizophrenia, anxiety disorder and its related diseases, depression, bipolar disorder, epilepsy, developmental disorders, sleep disorders, and other neuropsychiatric diseases; and drug dependence, cognitive disorders, Alzheimer's disease, Huntington's chorea, Parkinson's disease, movement disorders associated with muscular rigidity, cerebral ischemia, cerebral insufficiency, spinal cord disorders, cephalopathy, and other neurological diseases.


Find Patent Forward Citations

Loading…